secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001558370-25-000576
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO and CFO to depart GlycoMimetics by March 31; will consult through merger close
--------------------------------------------------------------------------------

- CEO Harout Semerjian and CFO Brian Hahn notified board of intent to resign by March 31, 2025.
- Both expected to enter consulting agreements through expected close of merger with Crescent Biopharma.
- Departures coincide with pending merger; no replacements named yet.
- Notice date: January 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025000576/0001558370-25-000576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025000576/glyc-20250129x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer